GlassScriptPhysician profile
Jeffrey D Nadelson
NPI 1619263399
$3,904.15
in general payments reported to CMS, 2019-2025
30 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $422 · 2021: $290 · 2022: $949 · 2023: $809 · 2024: $214 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.68 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $416.82 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $411.32 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $294.42 | 2022-2025 | |
| Celgene Corporation | $175.92 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $148.61 | 2022-2023 | |
| Pfizer INC. | $135.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $135.77 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $117.51 | 2022-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.79 | 2019-2025 | Xifaxan |
| Boston Scientific Corporation | $100.00 | 2019 | |
| Redhill Biopharma INC. | $74.76 | 2020-2022 | |
| Amgen INC. | $67.21 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $54.21 | 2022 | |
| Intercept Pharmaceuticals, INC. | $53.24 | 2020-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $46.39 | 2024-2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.80 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $42.95 | 2020-2023 | Sutab |
| Madrigal Pharmaceuticals | $42.73 | 2025 | Rezdiffra |
| Organon LLC | $39.07 | 2023 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $34.98 | 2020-2021 | |
| Genzyme Corporation | $25.95 | 2023 | |
| Qol Medical, LLC | $25.79 | 2023 | Sucraid |
| Ardelyx, INC. | $24.33 | 2024 | Ibsrela |
| Celltrion USA INC. | $24.07 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $23.64 | 2022 | |
| Novo Nordisk INC | $21.62 | 2025 | Wegovy |
| Shionogi INC | $18.62 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.09 | 2019 | |
| Alfasigma USA, INC. | $16.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nadelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.